Begin typing your search above and press return to search.

India likely to permit Pfizer vaccines in India, drugmaker to get conditional indemnity!

By:  Tupaki Desk   |   15 May 2021 7:48 AM GMT
India likely to permit Pfizer vaccines in India, drugmaker to get conditional indemnity!
X
Despite the dip in new infections, India has been seeing more than three lakh new Covid infections. Foreign experts attribute the surge in cases and casualties to the low vaccination numbers in the countries and advised the Indian government to focus on ramping up the vaccination drive.

As a result of the shortage of vaccine doses, several states have halted the ongoing vaccination drive and are waiting for the vaccine supply so that the vaccination drive can be carried out.

To counter the shortage in vaccine supply, the Centre is making ways for more vaccines. The other day, Russia's Sputnik was officially launched in India and will be used in the vaccination drive very soon.

Now it is said that the Union Government might grant permission for Pfizer and other drugmakers to enter India. Pfizer is facing allegations of adverse effects. For the same reason, earlier India has not allowed Pfizer.

Several media reports claimed that the series of meetings between government and officials of Pfizer came to a conclusion over the issue of indemnifying the company against liabilities that may arise from any side- effects after using its vaccines.

In its story, The Economics Times said that the Centre is likely to give permission for emergency use of vaccines with some restrictions and the Centre allegedly agreed to pay conditional compensation for the company.

If everything would have gone as per plan, Pfizer would have gotten permission for the emergency usage. Pfizer failed to submit the details asked by the Drugs Controller General of India(DCGI).

The US-based drug maker even pulled back its application to get permission for the vaccine usage. On the other hand, there are some doubts about the efficiency offered by the Pfizer vaccine.